RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsAn ASCO Meeting Abstract from the 2022 ASCO Annual Meeting has cited that the average cost for the first year of HR+/HER2 negative was US$192,367 per patient. With ONCY stating that approximately 55,000 women would become eligible for 3rd line pelareorep + paclitaxel treatment, and a per patient cost of US$192K, this patient group would translate into approximately US$10.56 Billion in annual sales for pelareorep in HR+/Her2 - mBC for ONCY or ONCY's Big Pharma acquirer.
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e18834